PDCD1 and neoplasm: The PD1-Vaxx vaccine (Imugene Ltd., Sydney, Australia) produces polyclonal antibodies that inhibit PD-1 in breast and pancreatic cancer cells [52], resulting in a significant decrease in tumor growth in mice [52].